Palivizumab

Drug Profile

Palivizumab

Alternative Names: MEDI-493; Synagis

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MedImmune
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Respiratory syncytial virus infections

Most Recent Events

  • 13 Jul 2017 AbbVie completes a phase IIIb trial for Respiratory syncytial virus infections in Belarus and Russia (IM) (NCT02968173)
  • 01 Nov 2016 AbbVie initiates a phase IIIb trial for Respiratory syncytial virus infections in Belarus (IM) after November 2016 (NCT02968173)
  • 01 Nov 2016 AbbVie initiates a phase IIIb trial for Respiratory syncytial virus infections in Russia (IM) (NCT02968173)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top